Amifostine improves hemodynamic parameters in doxorubicin-pretreated rabbits

Pharmacological Reports

Volumn 58, Issue 6, 2006, Pages 966-972

  Potemski, Piotr ^a   Polakowski, Przedzisław ^a   Wiktorowska Owczarek, Anna K ^a   Owczarek, Jacek ^a   Płuzańska, Anna ^a   Orszulak Michalak, Daria ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Amifostine; Cardiotoxicity; Doxorubicin; Rabbits

Indexed keywords

ALBUMIN I 125; AMIFOSTINE; DOXORUBICIN; SODIUM CHLORIDE;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CALCULATION; CARDIOTOXICITY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; FEMALE; HEART INDEX; HEART OUTPUT; HEMODYNAMICS; MALE; NONHUMAN; VASCULAR RESISTANCE;

EID: 33846320092     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Adachi K, Fujiura. Y, Mayumi F, Nozuhara A, Sugiu Y, Sakanashi T, Hidaka T, Toshima H: A deletion of mitochondrial DNA in murine doxorubicin-induced cardiotoxicity. Biochem Biophys Res Commun, 1993, 195, 945-951.
2. Arnolda L, McGrath B, Cocks M, Sumithran E, Johnston C: Adriamycin cardiomyopathy in the rabbit: an animal model of low output cardiac failure with activation of vasoconstrictor mechanisms. Cardiovasc Res, 1985, 19, 378-382.
3. Attie MF, Fallon MD, Spar B, Wolf JS, Slatopolsky E, Goldfarb S: Bone and parathyroid inhibitory effects of S-2(3-aminopropylamino)ethylphosphorothioic acid. Studies in experimental animals and cultured bone cells. J Clin Invest, 1985, 75, 1191-1197.
4. Bhanumathi P, Saleesh ED, Vasudevan DM: WR-1065 as a chemoprotector in adriamycin chemotherapy. Cancer Lett, 1994, 81, 171-175.
5. Bolaman Z, Cicek C, Kadikoylu G, Barutca S, Serter M, Yenisey C, Alper G: The protective effects of amifostine on adriamycin-induced acute cardiotoxicity in rats. Tohoku J Exp Med, 2005, 207, 249-253.
6. Bristow MR, Minobe WA, Billingham ME, Marmor JB, Johnson GA, Ishimoto BM, Sageman WS, Daniels JR: Anthracycline-associated cardiac and renal damage in rabbits. Evidence for mediation by vasoactive substances. Lab Invest, 1981, 45, 157-168.
7. Dorr RT, Lagel K, McLean S: Cardioprevention of rat heart myocytes with amifostine (Ethyol) and its free thiol, WR-1065, in vitro. Eur J Cancer, 1996, 23A, Suppl 4, 21-25.
8. Dragojevic-Simic VM, Dobric SL, Bokonjic DR, Vucinic ZM, Sinovec SM, Jacevic VM, Dogovic NP: Amifostine protection against doxorubicin cardiotoxicity in rats. Anticancer Drugs, 2004, 15, 169-178.
9. Durand RE: Radioprotection by WR-2721 in vitro at low oxygen tensions: implications for its mechanisms of action. Br J Cancer, 1983, 47, 387-392.
10. Goormaghtigh E, Huart P, Praet M, Brasseur R, Ruysschaert JM: Structure of the adriamycin-cardiolipine complex: role in mitochondrial toxicity. Biophys Chem, 1990, 35, 247-257.
11. Green D, Schein P: WR-2721 chemoprotects for doxorubicin (dox) toxicity: preclinical studies (Meeting abstract). Proc Annu Meet Am Assoc Cancer Res, 1993, 34, A2606.
12. Gustafson DL, Swanson JD, Pritsos CA: Modulation of glutathione and glutathione dependent antioxidant enzymes in mouse heart following doxorubicin therapy. Free Radic Res Commun, 1993, 19, 111-120.
13. Herman EH, Zhang J, Chadwick DP, Ferrans VJ: Comparison of the protective effect of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats. Cancer Chemother Pharmacol, 2000, 45, 329-334.
14. Herrera JL, Vigneulle RM, Gage T, MacVittie TJ, Nold JB, Dubois A: Effect of radiation and radioprotection on small intestinal function in canines. Dig Dis Sci, 1995, 40, 211-218.
15. 60Co γ-ray irradiation. Carcinogenesis, 1986, 7, 665-668.
16. Hou M, Chrysis D, Nurmio M, Parvinen M, Eksborg S, Soder O, Jahnukainen K: Doxorubicin induces apoptosis in germ line stem cells in the immature rat testis and amifostine cannot protect against this cytotoxicity. Cancer Res, 2005, 65, 9999-10005.
17. Ishikawa N, Hagino Y, Shigei T: Incidence of epinephrine-induced pulmonary edema in rabbits and accompanying metabolic changes. Jpn J Pharmacol, 1975, 25, 681-686.
18. Isoda H, Akagi K, Murata T, Aoki Y, Ikeda S, Tanaka Y, Kihara T, Ikeda M: Change in ascorbate radical production in an irradiated experimental tumor with increased tumor size. Cancer Res, 1996, 56, 5741-5744.
19. Jaenke RS: Delayed and progressive myocardial lesions after adriamycin administration in the rabbit. Cancer Res, 1976, 36, 2958-2966.
20. Jahnukainen K, Jahnukainen T, Salmi TT, Svechnikov K, Eksborg S, Soder O: Amifostine protects against early but not late toxic effects of doxorubicin in infant rats. Cancer Res, 2001, 61, 6423-6427.
21. Jasińska M, Owczarek J, Orszulak-Michalak D: Influence of simvastatin at high dose and nifedipine on hemodynamic parameters in rabbits. Pharmacol Rep, 2006, 58, 48-59.
22. Kang YJ, Chen Y, Epstein PN: Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice. J Biol Chem, 1996, 271, 12610-12616.
23. Korner PI, Uther JB, White SW: Circulatory effects of chloralose-urethane and sodium pentobarbitone anaesthesis in the rabbit. J Physiol, 1968, 199, 253-265.
24. Long HJ, Diamond SS, Raflo CP, Burningham RA: Dose-response relationships of chronic adriamycin toxicity in rabbits. Eur J Cancer Clin Oncol, 1984, 20, 129-135.
25. Marzatico F, Porta C, Moroni M, Bertorelli L, Borasio E, Finotti N, Pansarasa O, Castagna L: In vitro antioxidant properties of amifostine (WR-2721, Ethyol). Cancer Chemother Pharmacol, 2000, 45, 172-176.
26. Minatoguchi S, Uno Y, Seishima M, Koshiji M, Kakami M, Yokoyama H, Ito H, Fujiwara H: Effects of adrenaline infusion on plasma lipids and noradrenaline levels in rabbits with adriamycin-induced cardiomyopathy. Clin Exp Pharmacol Physiol, 1997, 24, 477-480.
27. Nazeyrollas P, Frances C, Prevost A, Costa B, Lorenzato M, Kantelip JP, Elaerts J, Millart H: Efficiency of amifostine as a protection against doxorubicin toxicity in rats during a 12-day treatment. Anticancer Res, 2003, 23(1A), 405-409.
28. Nazeyrollas P, Prevost A, Baccard N, Manot L, Devillier P, Millart H: Effects of amifostine on perfused isolated rat heart and on acute doxorubicin-induced cardiotoxicity. Cancer Chemother Pharmacol, 1999, 43, 227-232.
29. Nowak D, Pierściński G, Drzewoski J: Ambroxol inhibits doxorubicin-induced lipid peroxidation in heart of mice. Free Radic Biol Med, 1995, 19, 659-663.
30. Pedrotti A, Bonjour JP, Guignard JP: Protection from hypoxemia-induced renal dysfunction by the thiophosphate WR-2721. Kidney Int, 1992, 41, 80-87.
31. Pye MP, Black M, Cobbe SM: Comparison in vivo and in vitro haemodynamic function in experimental heart failure: use of echocardiography. Cardiovasc Res, 1996, 31, 873-881.
32. Rajagopalan S, Politi PM, Sinha BY, Myers CE: Adriamycin-induced free radical formation in the perfused rat heart: implications for the cardiotoxicity. Cancer Res, 1998, 48, 4766-4769.
33. Rigatos SK, Stathopoulos GP, Dontas I, Perrea-Kotsarelis D, Couris E, Karayannacos PE, Deliconstantinos G: Investigation of doxorubicin tissue toxicity: does amifostine provide chemoprotection? An experimental study. Anticancer Res, 2002, 22(1A), 129-134.
34. Rózalski M, Mirowski M, Balcerczak E, Krajewska U, Mlynarski W, Wierzbicki R: Induction of caspase 3 activity, bcl-2 bax and p65 gene expression modulation in human acute promyelocytic leukemia HL-60 cells by doxorubicin with amifostine. Pharmacol Rep, 2005, 57, 360-366.
35. Ryan SV, Carrithers SL, Parkinson SJ, Skurk C, Nuss C, Pooler PM, Owen CS et al.: Hypotensive mechanisms of amifostine. J Clin Pharmacol, 1996, 36, 365-373.
36. Solcia E, Ballerini L, Bellini O, Magrini U, Bertazzoli C, Tosana G, Sala L et al.: Cardiomyopathy of doxorubicin in experimental animals. Factors affecting the severity, distribution and evolution of myocardial lesions. Tumori, 1981, 67, 461-472.
37. Spencer CM, Goa KL: Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as radioprotector and cytotoxic chemoprotector. Drugs, 1995, 50, 1001-1031.
38. Stolarska M, Młynarski W, Zalewska-Szewczyk B, Bodalski J: Cytoprotective effect of amifostine in the treatment of childhood neoplastic diseases - a clinical study including the pharmacoeconomic analysis. Pharmacol Rep, 2006, 58, 30-34.
39. Wanless RB, Anand IS, Poole-Wilson PA, Harris P: An experimental model of chronic cardiac failure using adriamycin in the rabbit: central haemodynamics and regional blood flow. Cardiovasc Res, 1987, 21, 7-13.
40. Wiktorowska-Owczarek A, Owczarek J, Obolewska A, Orszulak-Michalak D: Effect of propranolol and midazolam therapy on hemodynamic parameters in rabbits. Med Sci Monit, 2000, 6, 896-900.
41. Yuhas JM: Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res, 1980, 40, 1519-1524.
42. Zieba R, Wagrowska-Danilewicz M: Influence of carnosine on the cardiotoxicity of doxorubicin in rabbits. Pol J Pharmacol, 2003, 55, 1079-1087.